Epoetin alfa (Eprex®) and quality of life

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 2, 2005, Pages

  Littlewood, Tim ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER PATIENT; FATIGUE; HEMOGLOBIN DETERMINATION; HUMAN; QUALITY OF LIFE; SHORT SURVEY; SYSTEMATIC REVIEW; ARTICLE; NEOPLASM; UNITED KINGDOM;

ANEMIA; EPOETIN ALFA; GREAT BRITAIN; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 24044522575     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. Barrett-Lee PJ, NBailey NP, O'Brien ME, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-7
2. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematological Oncology 2001;19:19-30.
3. Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multicentre patient survey. Cancer Fatigue Forum. Annals of Oncology 2000;11:971-5
4. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-74
5. Fallowfield L, et al. Multivariate regression analyses of data from a randomised, double blind, placebo controlled study to confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002; 87: 1341-53 [See also S9-11 of this issue]
6. Cella D, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anaemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21(2): 366-73 [See also S12-15 of this issue]
7. Jones, et al. Cancer 2004/5 in press [See also S16-18 of this issue]
8. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQoL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39; 335-45 [See also S3-5 of this issue]
9. Fairclough DL, Gagnon DD, Zagari MJ, et al. Evaluation of quality of life in a clinical trial with non-random dropout: the effect of epoetin alfa in anaemic cancer patients. Qual Life Res. 2003; 12(8): 1013-27 [See also S6-8 of this issue]
10. Littlewood TJ, Zagari M, Pallister C, et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anaemic cancer patients. The Oncologist 2003; 8(1): 99-107 [See also S19-21 of this issue]